Fabio Pammolli, Gianluca Baio, Armando Rungi

The price of pharmaceutical products in Italy. On some recent trends

  • Abstract

Informations and abstract

Keywords: Health Care Markets; Administered Prices; Pricing Policy; Price Convergence; Access Divergence; Health Technology Assessment.

The paper analyses some recent trends in the evolution of pharmaceutical markets and expenditure. The tension between an increasing difficulty of pharmaceutical R&D for new therapeutic indications and rigid budget constraints for States and institutional buyers can be faced through a further development and diffusion of value-based, performance- based, evaluation methods. The history of pharmaceutical pricing regulation in Italy and some of the challenges faced in the creation of a Single Market for medicines, show that pricing decisions cannot rely on cost plus methods, or on external reference pricing algorithms. Health technology assessment techniques can sustain a framework to assess and quantify the value of pharmaceutical innovation. In particular, Hta-based schemes tend to induce a continuous re-assessment of available evidence, before and after marketing authorization; this calls for a further improvement of information processing and analysis techniques by regulatory agencies, also based on observational data, such as those deriving from administrative database or registries.

Trova nel catalogo di Worldcat

Article first page

Article first page